AUTHORS
Minghui Duan, MD, Wenqi Zheng2, Tingting Cui3, Na Wei4, Long Chang, MD5, Hao Cai6
AFFILIATIONS
1 Peking Union Medical College Hospital, Beijing, China
2 Beijing No.6 Hospital, Beijing, China
3 Beijing No.6 Hospital, Beijing, China
4 Beijing No.6 Hospital, Beijing, China
5 Peking Union Medical College Hospital, Beijing, China
6 Peking Union Medical College Hospital, Beijing, China
ABSTRACT
Introduction
Gecacitinib (GCA) is a novel dual JAK/ACVR1 inhibitor. In a phase 3 study in JAK inhibitor (JAKi)-naïve patients (pts) with myelofibrosis, GCA showed superior spleen response and symptom improvement versus hydroxyurea (HU), with a manageable safety profile, particularly a low incidence of anemia. Pegylated interferon (PegIFN) is a main choice for cytoreductive therapy in polycythemia vera (PV). Combination therapy with a JAKi and PegIFN can induce both hematologic and molecular responses in pts with PV (Blood Adv. 2024;8(20):5416–5425); however, anemia occurred in 88% of pts, an adverse event (AE) that partly offset the efficacy benefit of the combination. The present study (NCT07445893) is evaluating the efficacy and safety of GCA plus PegIFN as first-line treatment in pts with PV.
Methods
This ongoing, single-arm, open-label, multicenter trial is enrolling pts aged ≥18 years with a diagnosis of PV according to the 2022 ICC criteria. Key inclusion criteria require at least one of the following disease manifestations: (a) HCT ≥45% and/or platelet count >400×10?/L and/or WBC ≥10×10?/L without phlebotomy; (b) constitutional symptoms; (c) progressive splenomegaly; or (d) history of thrombosis or bleeding events. Pts with prior exposure to PegIFN and/or a JAK inhibitor are excluded. However, pts who have received hydroxyurea or phlebotomy, or whose previous interferon was stopped ≥6 months earlier for reasons other than resistance/intolerance, are eligible for enrollment. Pts are to receive GCA 100 mg twice daily (BID) orally plus PegIFNα-2b 90 µg subcutaneously once weekly until loss of efficacy, intolerance, or disease progression. Dosage will be individually adjusted based on hematologic parameters. The primary endpoint is the hematologic response (HR) rate at week 24, defined as HCT <45%, WBC <10×10?/L, and PLT ≤400×10?/L. Key secondary endpoints include HCT response, spleen reduction, molecular response, improvement in MPN-SAF TSS, and safety.
Results
As of 24 July 2026, 9 pts with PV were enrolled in the study. Median treatment duration was 11.3 weeks (2.3-16.4). At baseline, median age was 49 years (29-66), and 7 (77.8%) pts were men. Four pts (44.4%) had a prior thrombotic event, and 5 pts (55.6%) were considered high risk based on prior thrombosis or age ≥60 years. The median time from diagnosis to the start of treatment was 0 years (0-6). Four pts (44.4%) had received HU treatment. Median JAK2V617F VAF was 64.0% (range, 14.5-94.2). Five pts had splenomegaly on ultrasound (One patient had massive splenomegaly without measurable spleen length recorded); median spleen length among the 4 pts with measured values was 14.4 cm (range 12.9-18.3 cm). Constitutional symptoms were present in only 1 patient.
All 3 evaluable patients (100%) achieved HR at week 12; one patient first met HR criteria as early as week 5. The HCT response rate was 100% (3/3), and the median HCT level decreased from 52% (range, 48.9-54.6%) to 41.2% (range, 39.1-43.7%). At week 12, spleen reduction was achieved in 1 of 2 evaluable pts with splenomegaly. Two of four evaluable pts achieved partial molecular response (a mean relative reduction in JAK2V617F VAF of 73.9% versus baseline).
The hematologic AEs included neutropenia (77.8%, including 5 pts with Grade 3), leukopenia (55.6%, including 2 pts with Grade 3), thrombocytopenia (44.4%, Grade 2), and anemia (11.1%, Grade 1). Neutropenia and thrombocytopenia were frequent and managed by dose adjustment, and recovered after dose adjustment. Non-hematologic AEs were low grade and comprised fatigue (33.3%), fever (22.2%), and increased aminotransferases, pruritus, and pain (each 11.1%). During the treatment, five pts (55.6%) required dose reduction or prolonged dosing intervals to control hematologic adverse events. No treatment discontinuations due to AEs were reported.
Conclusions
GCA in combination with PegIFNα-2b shows a manageable safety profile and robust hematologic efficacy in first-line PV pts. Individualized dose adjustments guided by tolerability can effectively manage hematologic AEs and support continued development of this combination as a first-line option in PV. Further follow-up is ongoing to mature week 24 primary endpoint and long-term safety data.
DISCLOSURES
Minghui Duan, MD: No relevant conflicts of interest to declare.